News Headlines

31. Genentech And Roche Break Ground On State-Of-The-Art Manufacturing Facility In Holly Springs, North Carolina 8/25/2025

    Genentech, a member of the Roche Group, today broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast.

32. Danforth Advisors Acquires PharmaDirections, Expanding Its Integrated Drug Development Services From Discovery Through Commercialization 8/25/2025

    Danforth Advisors, LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization.

33. Cambrex Expands Peptide Manufacturing Capabilities In Waltham, Massachusetts 8/25/2025

    Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts to further support the development and manufacturing of peptide therapies.

34. Johnson & Johnson Continues U.S. Investment With $2B Commitment To Enable Manufacturing At State-Of-The-Art North Carolina Facility 8/21/2025

    Johnson & Johnson (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, announced today it will increase its presence in North Carolina with a 160,000+ square foot dedicated manufacturing facility at FUJIFILM’s new biopharmaceutical manufacturing site in Holly Springs, North Carolina.

35. Thermo Fisher Scientific Opens Manufacturing Center Of Excellence Site In North Carolina 8/21/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C.

36. AAHI Partners With Quratis To Strengthen Global Vaccine Manufacturing And Accelerate Access To Lifesaving Vaccines 8/21/2025

    Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world.

37. Andelyn Biosciences And Amplo Biotechnology Partner To Manufacture Novel Gene Therapies For Diseases Affecting The Neuromuscular Junction 8/21/2025

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Amplo Biotechnology, a pioneer in adeno-associated virus (AAV) regenerative medicines for neuromuscular junction (NMJ) affecting conditions.

38. Piramal Pharma Solutions And NewAmsterdam Pharma Invest In Dedicated Suite To Enhance Oral Solid Dosage Production Capabilities At Piramal's Sellersville, Pennsylvania Site 8/21/2025

    Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA.

39. Jazz Pharmaceuticals Enters Exclusive Licensing Agreement With Saniona To Develop And Commercialize SAN2355 8/20/2025

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications, designed to overcome the limitations of non-selective Kv7-targeting compounds.

40. ACROBiosystems And DAAN Biotherapeutics Sign Strategic MOU For The Development Of Precision Immuno-Oncology Therapeutics 8/20/2025

    ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology therapeutics.